GI Motility Agents Do Not Need Dedicated CV Safety Studies, Panel Says
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Gastrointestinal Drugs Advisory Committee overwhelmingly opposes CV-specific studies for the class of 5-HT4 receptor agonists, but says Phase III trials should include patients at high risk for events.